Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Dianthus Therapeutics’ quarter ended September 30, 2026 financial results.
Dianthus Therapeutics, Inc. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Dianthus Therapeutics’ quarter ended September 30, 2026 financial results
- Exhibit 99.1 contains the detailed earnings figures and management commentary
- Results announcement provides the latest update on operating performance and financial position
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss $46.6M, or $0.81 per share, versus $36.8M, or $0.97, year over year
- Cash, equivalents and investments $1.2B at September 30, 2026, supporting projected runway into 2030
- CAPTIVATE interim responder rate 75% among first 40 CIDP participants, exceeding the 50% target
- Claseprubart catalysts: MMN Phase 2 results December 2026, CIDP Part A by year-end 2027, gMG Phase 3 in 2H 2028
- R&D expense $45.6M, up from $32.5M, reflecting expanded Phase 2 and Phase 3 development spending
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dianthus Therapeutics, Inc. /DE/ 8-K filings
Get the next DNTH 8-K as it lands
Follow DNTH for push alerts, or ask the research agent what this filing means.